Vivos Therapeutics, Inc. (VVOS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vivos Therapeutics, Inc. (VVOS) Healthcare & Pipeline Overview

Vivos Therapeutics, Inc. develops and commercializes the Vivos Method, a non-surgical, non-pharmaceutical treatment for dentofacial abnormalities, OSA, and snoring. Targeting general dentists in the United States and Canada, Vivos distinguishes itself through its non-invasive approach to treating sleep-related breathing disorders and related conditions, addressing a significant market need within the medical devices sector.

What Is the Investment Thesis for VVOS?

Vivos Therapeutics presents a compelling, albeit high-risk, investment opportunity within the medical device sector. The company's innovative Vivos Method offers a non-invasive alternative to traditional OSA treatments, potentially capturing a significant share of the growing market for sleep-related breathing disorder solutions. Key value drivers include the expansion of the Vivos Method certified provider network and increasing awareness among patients and healthcare professionals. However, the company's negative profit margin of -98.8% and a high debt-to-equity ratio of 493.60 indicate significant financial challenges. The company's future success hinges on its ability to scale its operations, achieve profitability, and effectively manage its debt burden. Investors should carefully consider these risks and the company's high beta of 7.02, indicating significant volatility, before making investment decisions.

Based on FMP financials and quantitative analysis

VVOS Key Highlights

Market capitalization of $3.88M, indicating a micro-cap company with high growth potential but also significant risk.

• Negative P/E ratio of -0.99, reflecting current losses and the need for improved profitability.
• Gross margin of 55.7%, suggesting a solid foundation for profitability if operating expenses can be managed effectively.
• Negative ROE of -335.5%, highlighting the company's current inefficiency in generating profits from equity.
• High beta of 7.02, indicating significant volatility compared to the overall market.

Who Are VVOS's Competitors?

VVOS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VVOS's Key Strengths?

Proprietary Vivos Method with patent protection.

• Non-invasive treatment approach appealing to patients.
• Training and certification program for dentists.
• Focus on addressing the underlying causes of OSA.

What Are VVOS's Weaknesses?

Negative profitability and high debt levels.

• Limited brand awareness compared to established competitors.
• Reliance on a network of certified providers for distribution.
• High beta indicating significant stock volatility.

What Could Drive VVOS Stock Higher?

Expansion of the Vivos Method provider network, increasing the availability of treatment to patients.

• Increased awareness and patient education campaigns highlighting the benefits of non-invasive OSA treatment.
• Potential regulatory approvals or clearances for new Vivos products or services.
• Strategic partnerships and collaborations with dental supply companies and sleep clinics.

What Are the Key Risks for VVOS?

Financial-distress signal — its Altman Z-Score of -11.24 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Negative profitability and high debt levels pose a significant financial risk.
• Competition from established players in the sleep apnea market could limit market share.
• Changes in regulatory requirements or reimbursement policies could impact revenue.
• Product liability claims could arise from the use of Vivos appliances.
• High beta indicates significant stock volatility, increasing investment risk.

What Are the Growth Opportunities for VVOS?

• Expansion of the Vivos Method Provider Network: Vivos has a significant opportunity to grow by expanding its network of certified dental professionals offering The Vivos Method. By increasing the number of trained providers, Vivos can reach a wider patient population and drive revenue growth. The market for dentists seeking to incorporate sleep apnea treatment into their practices is substantial, with potential for significant expansion in both the United States and Canada. The timeline for this growth is ongoing, with continuous recruitment and training efforts.
• Increased Awareness and Patient Education: A key growth driver for Vivos is increasing awareness among patients and healthcare professionals about the benefits of The Vivos Method. By educating potential patients about the non-invasive nature and potential long-term benefits of the treatment, Vivos can drive demand and increase adoption. This can be achieved through targeted marketing campaigns, online resources, and partnerships with sleep clinics and other healthcare providers. The timeline for this growth is ongoing, with continuous marketing and education initiatives.
• Development of New Products and Services: Vivos can expand its product and service offerings to address a wider range of patient needs and generate additional revenue streams. This could include the development of new oral appliances, diagnostic tools, or treatment protocols. By innovating and expanding its portfolio, Vivos can strengthen its competitive position and attract new customers. The timeline for this growth is medium-term, with potential for new product launches in the next 2-3 years.
• Strategic Partnerships and Collaborations: Vivos can leverage strategic partnerships and collaborations to expand its reach and accelerate growth. This could include partnerships with dental supply companies, sleep clinics, or other healthcare organizations. By collaborating with established players in the industry, Vivos can gain access to new markets, technologies, and expertise. The timeline for this growth is ongoing, with continuous exploration of potential partnership opportunities.
• International Expansion: While currently focused on the United States and Canada, Vivos has the potential to expand its operations into international markets. The global market for sleep apnea treatment is substantial, with significant opportunities in Europe, Asia, and other regions. By expanding its geographic reach, Vivos can tap into new customer bases and drive long-term growth. The timeline for this growth is long-term, with potential for international expansion in the next 3-5 years.

What Are VVOS's Competitive Advantages?

• Proprietary Vivos Method: The Vivos Method is a unique and patented treatment modality that differentiates the company from competitors.
• Training and Certification Program: The company's training and certification program creates a barrier to entry, as dentists must be trained and certified to administer The Vivos Method.
• Established Network of Providers: Vivos has built a network of certified dental providers, creating a distribution channel and brand recognition.
• Non-Invasive Approach: The non-invasive nature of The Vivos Method appeals to patients seeking alternatives to traditional OSA treatments.

What Does VVOS Do?

Vivos Therapeutics, Inc., founded in 2016 and headquartered in Littleton, Colorado, is a medical technology company dedicated to developing and commercializing innovative treatment modalities for patients suffering from dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring. The company's flagship offering is The Vivos Method, a non-invasive, non-surgical, and non-pharmaceutical approach designed to address the underlying causes of these conditions. This multi-disciplinary treatment modality aims to provide a comprehensive solution for patients seeking alternatives to traditional interventions. The Vivos Method involves the use of custom-made oral appliances that gently and gradually remodel and realign the upper and lower jaws, thereby expanding the airway and improving breathing. This method is primarily marketed to licensed professionals, particularly general dentists, who are trained and certified to administer the Vivos treatment protocol. Vivos provides these dentists with the necessary appliances, training, and support to effectively integrate The Vivos Method into their practices. In addition to The Vivos Method, the company offers the VivoScore Program, a screening and home sleep test designed for both adults and children. This program enables dentists to identify potential cases of OSA and dentofacial abnormalities, facilitating early intervention and treatment planning. By providing a comprehensive suite of products and services, Vivos aims to empower dentists to address a wider range of patient needs and improve overall oral and systemic health. Originally known as Vivos BioTechnologies, Inc., the company rebranded as Vivos Therapeutics, Inc. in March 2018, reflecting its focus on therapeutic solutions. The company's geographic focus is primarily the United States and Canada, where it actively markets and sells its appliances, treatments, and related services to a growing network of licensed dental professionals.

What Products and Services Does VVOS Offer?

• Develops and commercializes The Vivos Method, a non-invasive treatment for dentofacial abnormalities, OSA, and snoring.
• Offers custom-made oral appliances designed to remodel and realign the jaws.
• Provides training and certification programs for general dentists to administer The Vivos Method.
• Markets and sells its appliances and related services to licensed dental professionals.
• Offers the VivoScore Program, a screening and home sleep test for adults and children.
• Focuses on addressing the underlying causes of sleep-disordered breathing.

How Does VVOS Make Money?

• Sells Vivos appliances to licensed dentists who have completed Vivos training programs.
• Generates revenue from training and certification fees for dentists.
• Offers the VivoScore Program, generating revenue from screening and home sleep tests.
• Provides ongoing support and resources to certified Vivos providers.

What Industry Does VVOS Operate In?

Vivos Therapeutics operates within the medical device industry, specifically targeting the market for sleep-disordered breathing solutions. The industry is characterized by increasing awareness of OSA and its associated health risks, driving demand for effective treatment options. The competitive landscape includes established players offering CPAP therapy, oral appliances, and surgical interventions. Vivos differentiates itself through its non-invasive, multi-disciplinary approach, aiming to address the underlying causes of OSA and dentofacial abnormalities.

Who Are VVOS's Key Customers?

• General dentists seeking to expand their practice offerings with sleep apnea treatment.
• Patients suffering from dentofacial abnormalities, OSA, and snoring.
• Children and adults seeking non-invasive alternatives to traditional OSA treatments.
• Sleep clinics and other healthcare providers interested in partnering with Vivos.

Wall Street analysts project Vivos Therapeutics, Inc. revenue of about $24.1M for fiscal 2026, with EPS near $-1.46. The estimate reflects 3 contributing analysts.

Vivos Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.6% below estimates on average.

Vivos Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.24 places it in the distress zone, a signal of elevated financial risk.

Vivos Therapeutics, Inc. (VVOS) Valuation Context

Valued at $3.88M, VVOS is classified as a micro-cap stock. Relative to its peer group, VVOS's quantitative score of 17/100 is below the peer average of 77/100.

VVOS Revenue & Earnings Trend

In Q2 2026, VVOS generated $5.2M in top-line revenue, marking a sequential increase of 0.2%. The company recorded a net loss of $5.5M, with diluted EPS of $-0.31. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, VVOS averaged $-0.52 in diluted EPS.

Company Profile

Vivos Therapeutics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Littleton, US. The company is led by CEO R. Kirk Huntsman. VVOS has traded publicly since 2020.

VVOS Financials

VVOS Latest News

VVOS Analyst Consensus

VVOS MoonshotScore

Latest Vivos Therapeutics, Inc. Analysis

VVOS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources